Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giovanni Roti

Showing results (61-70 of 73) with videos related to

Pageof 8
Sort By:
Haematologica|March 18, 2024
Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II studyEmilio Iannitto, Simone Ferrero, Côme Bommier, et al.
The New England Journal of Medicine|December 30, 2025
Direct-Acting Antiviral Agents in Hepatitis C-Associated Indolent LymphomasMichele Merli, Elisa Genuardi, Silvia Zibellini, et al.
Blood|May 25, 2006
Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemiaBrunangelo Falini, Maria Paola Martelli, Niccolò Bolli, et al.
Plos One|February 18, 2010
Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptorsMiguel Aste-Amézaga, Ningyan Zhang, Janet E Lineberger, et al.
Genes|June 26, 2025
Genetics of Darier's Disease: New Insights into Pathogenic MechanismsBarbara Moschella, Sabrina Busciglio, Enrico Ambrosini, et al.
Cancers|June 24, 2022
Prevalence and Prognostic Role of IDH Mutations in Acute Myeloid Leukemia: Results of the GIMEMA AML1516 ProtocolMonica Messina, Alfonso Piciocchi, Tiziana Ottone, et al.
Nature Communications|June 4, 2024
Orthogonal proteogenomic analysis identifies the druggable PA2G4-MYC axis in 3q26 AMLMatteo Marchesini, Andrea Gherli, Elisa Simoncini, et al.
Cancer Discovery|August 23, 2020
The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting TherapiesAngela Su, Frank Ling, Camille Vaganay, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 25, 2024
End of induction [<sup>18</sup>F]FDG PET is prognostic for progression-free survival and overall survival in follicular lymphoma patients enrolled in the FOLL12 trialLuca Guerra, Stephane Chauvie, Federico Fallanca, et al.
Blood|March 6, 2026
Deregulation of FOXF1/FENDRR from t(14;16)(q32;q24) defines a subtype of high-risk lineage ambiguous leukemiaDanika Di Giacomo, Petri Pölönen, Valentina Bardelli, et al.
Pageof 8

Showing results (61-70 of 73) with videos related to

Sort By:
Pageof 8
Haematologica|March 18, 2024
Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II studyEmilio Iannitto, Simone Ferrero, Côme Bommier, et al.
The New England Journal of Medicine|December 30, 2025
Direct-Acting Antiviral Agents in Hepatitis C-Associated Indolent LymphomasMichele Merli, Elisa Genuardi, Silvia Zibellini, et al.
Blood|May 25, 2006
Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemiaBrunangelo Falini, Maria Paola Martelli, Niccolò Bolli, et al.
Plos One|February 18, 2010
Characterization of Notch1 antibodies that inhibit signaling of both normal and mutated Notch1 receptorsMiguel Aste-Amézaga, Ningyan Zhang, Janet E Lineberger, et al.
Genes|June 26, 2025
Genetics of Darier's Disease: New Insights into Pathogenic MechanismsBarbara Moschella, Sabrina Busciglio, Enrico Ambrosini, et al.
Cancers|June 24, 2022
Prevalence and Prognostic Role of IDH Mutations in Acute Myeloid Leukemia: Results of the GIMEMA AML1516 ProtocolMonica Messina, Alfonso Piciocchi, Tiziana Ottone, et al.
Nature Communications|June 4, 2024
Orthogonal proteogenomic analysis identifies the druggable PA2G4-MYC axis in 3q26 AMLMatteo Marchesini, Andrea Gherli, Elisa Simoncini, et al.
Cancer Discovery|August 23, 2020
The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting TherapiesAngela Su, Frank Ling, Camille Vaganay, et al.
European Journal of Nuclear Medicine and Molecular Imaging|May 25, 2024
End of induction [<sup>18</sup>F]FDG PET is prognostic for progression-free survival and overall survival in follicular lymphoma patients enrolled in the FOLL12 trialLuca Guerra, Stephane Chauvie, Federico Fallanca, et al.
Blood|March 6, 2026
Deregulation of FOXF1/FENDRR from t(14;16)(q32;q24) defines a subtype of high-risk lineage ambiguous leukemiaDanika Di Giacomo, Petri Pölönen, Valentina Bardelli, et al.
Pageof 8